Journal
JOURNAL OF CLINICAL ONCOLOGY
Volume 23, Issue 26, Pages 6387-6393Publisher
AMER SOC CLINICAL ONCOLOGY
DOI: 10.1200/JCO.2005.05.015
Keywords
-
Categories
Ask authors/readers for more resources
This article is a review of the improvement in the treatment of patients with diffuse large B-cell lymphoma made during the last 10 years. Patients with diffuse large B-cell lymphoma now have a better outcome with longer survival because of two major developments: (1) increasing the dose of active drugs with shortening the time between cycles, resulting in dose-dense and/or dose-intense regimens; and (2) combining rituximab with chemotherapy. Both strategies were associated with higher response rates, lower relapse rates, longer event-free survival, longer time to progression, and longer overall survival, particularly in patients without adverse prognostic parameters. A combination of dose-dense, dose-intense regimens plus rituximab is currently being tested for poor-risk patients with diffuse large B-cell lymphoma. However, much work has to be done for patients with high-risk lymphoma. it may come with a better definition of genetic abnormalities specifically associated with refractoriness to chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available